Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors
Journal of Medicinal Chemistry2012Vol. 55(24), pp. 10797–10822
Citations Over TimeTop 10% of 2012 papers
Abstract
The recent launch onto the market of five VEGFR inhibitors indicates the therapeutic value of these agents and the importance of the research in the field of angiogenesis inhibitors for future oncologic therapy. In this Perspective we briefly report the inhibitors that are in clinical use, while we dedicate two wider sections to the compounds that are in clinical trials and to the new derivatives appearing in the literature. We especially consider the medicinal chemistry aspect of the topic and report the structure-activity relationship studies and the binding mode of some inhibitors as well as the biological data of the compounds discovered in the past 5 years.
Related Papers
- → Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors(2013)144 cited
- → Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings(2016)19 cited
- → Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma(2012)
- → Περιεγχειρητική διακύμανση του αυξητικού παράγοντα αγγειακού ενδοθηλίου (vascular endothelial growth factor/VEGF) σε ασθενείς με καρκίνο παχέος εντέρου και ασθενείς με καρκίνο μαστού(2013)